This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Nauck, M. A Search for Related Content Social Bookmarking                         What's this?

Liraglutide, a once-daily human GLP-1 analogue

Diabeteszentrum, Bad Lauterberg, Germany, M.Nauck{at}diabeteszentrum.de

Glucagon-like peptide-1 (GLP-1) is an incretin hormone physiologically playing a role in glucose homeostasis, together with the partner incretin, glucose dependent insulinotropic peptide (GIP). Active concentrations of this hormone are not maintained for long because of its very rapid degradation and elimination. The effects of the hormone are of potential therapeutic value in type 2 diabetes; therefore, analogues of GLP-1 have been developed that are characterised by a prolonged circulating half-life relative to the naturally occurring hormone. One such long-acting analogue is liraglutide. The effects of liraglutide are maintained over 24 h, allowing once-daily dosing. Liraglutide provides all of the beneficial actions of endogenous GLP-1: glucose-dependent stimulation of insulin secretion, glucagon suppression, deceleration of gastric emptying, appetite suppression/weight loss and, in animal models, inhibition of β-cell apoptosis and promotion of β-cell regeneration. Because liraglutide stimulates insulin secretion and suppresses glucagon secretion only when blood glucose levels are elevated, the risk of treatment-associated hypoglycaemia is low. In clinical studies, liraglutide substantially lowered fasting and postprandial glucose concentrations, with an overall reduction in haemoglobin A_1c of up to 1-2%. In some studies, liraglutide has decreased several biomarkers of cardiovascular risk and lowered triglyceride levels significantly. Side effects most commonly are gastrointestinal symptoms; they are usually mild to moderate and resolve over time. Long-term clinical trials are needed to assess whether the effects of liraglutide on the β cell translate into a durable improvement in β-cell function and mass in patients with type 2 diabetes and, if so, whether this will slow or halt disease progression and help prevent complications. Br J Diabetes Vasc Dis, 2008; 8 (Suppl 2): S26—S33

Key Words: glucagon-like peptide-1 • haemoglobin A1c • liraglutide • type 2 diabetes • weight loss

References

• Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocrine Rev 1998;19:477-90.[Abstract/Free Full Text]
• Magnusson I., Rothman DL, Katz LD et al. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest 1992;90:1323-7.[Web of Science][Medline] [Order article via Infotrieve]
• Shah P., Vella A., Basu A. et al. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000;85:4053-9.[Abstract/Free Full Text]
• Vilsbøll T., Krarup T., Deacon CF et al. Reduced postprandial concentrations of intact, biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001;50:609-13.[Abstract/Free Full Text]
• American Diabetes Association. Complications of Diabetes in the United States. http://www.diabetes.org/type-2-diabetes/well-being/heart-disease-and-stroke.jsp. (Accessed 10 April 2007)
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patient with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Saydah SH, Fradkin J., Cowie CC Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-42.[Abstract/Free Full Text]
• Knudsen LB, Nielsen PF, Huusfeldt PO et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000;41:1664-9.
• Agersø H., Jensen LB, Elbrønd B. et al. The pharmacokinetics, pharmacodynamics, safety, and tolerability of NN2211, a new long-active GLP-1 derivative, in healthy men. Diabetologia 2002; 465:195-202.
• Elbrønd B., Jakobsen G., Larsen S. et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002;25:1398-404.[Abstract/Free Full Text]
• Chang AM, Jakobsen G., Sturis J. et al. The GLP-1 derivative NN2211 restores β-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2005;52:1786-91.[CrossRef]
• Madsbad S., Schmitz O., Ranstam J. et al. On behalf of the NN2211-1310 International Study Group: Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211). A 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004;27:1335-42.[Abstract/Free Full Text]
• Feinglos MN, Saad MF, Pi-Sunyer FX et al. Liraglutide Dose-Response Study Group. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes. Diabet Med 2005;22:1016-23.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Nauck MA, Hompesch M., Filipczak R. et al. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006;114:417-23.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Nauck MA, El-Ouaghlidi A., Hompesch M. et al. No impairment of hypoglycemia counterregulation via glucagon with NN221, a GLP-1 derivative, in subjects with type 2 diabetes. Diabetes 2003;52(suppl 1):A128.
• Meier JJ, Gallwitz B., Salmen S. et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003;88:2719-25.[Abstract/Free Full Text]
• Juhl CB, Hollingdal M., Sturis J. et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002; 51:424-9.[Abstract/Free Full Text]
• Byetta® (exenatide injection) [product information]. San Diego: Amylin Pharmaceuticals and Indianapolis: Eli Lilly and Company, 2007.
• Degn KB, Juhl CB, Sturis J. et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and - and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004;53:1187-94.[Abstract/Free Full Text]
• Vilsbøll T., Zdravkovic M., Le-Thi T. et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007;30:1608-10.[Free Full Text]
• Novo Nordisk (data on file).
• Haffner SM, Lehto S., Ronnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.[Abstract/Free Full Text]
• Vilsbøll T., Zdravkovic M., Le-Thi T. et al. Liraglutide treatment, blood pressure and biomarkers of cardiovascular risk in patients with type 2 diabetes: 14 weeks monotherapy study. Diabetes 2006;55(suppl 1):A465.
• Sturis J., Gotfredsen CF, Rømer J. et al. GLP-1 derivative liraglutide in rats with β-cell deficiencies: influence of metabolic state on β-cell mass dynamics. Br J Pharmacol 2003;140:123-32.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Rolin B., Larsen MO, Gotfredsen CF et al. The long-active GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002;283:E745-52.[Abstract/Free Full Text]
• Bregenholt S., Moldrup A., Blume N. et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro. J Biochem Biophys Res Comm 2005;330:577-84.[CrossRef]
• Friedrichsen BN, Neubauer N., Lee YC et al. Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways. J Endocrinol 2006;88:481-92.

The British Journal of Diabetes & Vascular Disease, Vol. 8, No. 2 Suppl, S26-S33 (2008)
DOI: 10.1177/1474651408100524


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Nauck, M. A Search for Related Content Social Bookmarking                         What's this?